|Title:||Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity|
|Abstract:||Disclosed herein is cis-oxalato (trans-1-1,2-cyclohexanediamine) Pt(II) optically high purity. Because of its complete optical purity, the compound is effective as raw material of such a medicine as a carcinostatic agent. The complete optical purity of the above compound may be proved by comparing the respective melting points of the cis-oxalato (trans-1-1,2-cyclohexanediamine).|
|Inventor(s):||Nakanishi; Chihiro (Kanagawa, JP), Ohnishi; Yuko (Kanagawa, JP), Ohnishi; Junji (Kanagawa, JP), Taniuchi; Junichi (Kanagawa, JP), Okamoto; Koji (Kanagawa, JP), Tozawa; Takeshi (Kanagawa, JP)|
|Assignee:||Tanaka Kikinzoku Kogyo K.K. (JP)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||5-019508||Jan 12, 1993|
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0567438||Jan 13, 1999|
|Germany||69322992||Aug 13, 2009|
|Japan||H06211883||Aug 02, 1994|
|Japan||H06287021||Oct 11, 1994|
|Germany||69322992||May 27, 1999|
|This preview shows a limited data set|
Subscribe for full access
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.